Bay City Capital GF Xinde
Bay City Capital GF Xinde is a cross-border life sciences venture capital fund with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. To learn more, visit www.baycitycapital.com or www.gf.com.cn.
Brunnur Ventures GP is the general partner of Brunnur VC Fund, an ISK 4bn (approx. USD 38m as of January 2018) venture capital fund established in 2015. The Fund invests in Icelandic start-up companies with innovative, scalable business models, extraordinary entrepreneurial talent and a strong competitive edge generated by patentable technology or exclusive, proprietary know-how. To learn more, visit www.brunnurventures.com
Novartis Venture Fund
Novartis Venture Fund is a financially driven corporate life science fund whose purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life sciences companies at various stages of their development. To learn more, visit www.nvfund.com.
Pivotal bioVenture Partners
Pivotal bioVenture Partners is a $300MM venture capital fund established in 2017. Based in San Francisco, California, the fund invests in US and European companies with a primary focus on innovative therapeutic solutions to major unmet medical needs. To learn more, visit www.pivotalbiovp.com.
Silfurberg is the private investment company of Mr. Fridrik Steinn Kristjánsson. Mr. Kristjánsson is the founder of two successful pharmaceutical companies, Invent Farma (sold to Apax partners in 2016) and Omega Farma (sold to Actavis in 2002).